As of Friday's close, ONCY had 4 analyst targets pointing to a significant amount of upside potential.
In fact, with an average target of $8.50, ONCY could have over 650% potential upside from its closing valuation on the 29th.
MarketBeat reports further that Patrick R. Trucchio of H.C. Wainwright has given ONCY a $10 target representing a potential upside over 800% from Friday's close.
Could (Nasdaq: ONCY) be undervalued from current chart levels? -----
#2. ONCY Potential Catalyst - An Interesting Chart Position Could Put ONCY On High Alert This Week.
Here was ONCY's 6-month chart at close on Friday.
As you can see above, ONCY closed above 4 key technical chart levels in its:
- 20-Day Simple Moving Average (SMA)
- 50-Day SMA
- 5-Day Exponential Moving Average (EMA)
- 13-Day EMA
With ONCY closing above those 4 levels Friday, could strong support be developing during a recent vertical chart burst that has seen this profile climb from the $.77 range over the past two weeks? -----
#3. ONCY Potential Catalyst - The Company Presents Translational Data From Key Trials At ASCO 2026.
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced translational data from the GOBLET and AWARE-1 trials will be presented at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting at McCormick Place, Chicago, Illinois, from May 29-June 2, 2026. Pelareorep is an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes.
“These findings demonstrate that pelareorep works by expanding preexisting tumor-reactive immune cells rather than introducing new antigens,” said Dr. Richard Vile, Ph.D., Professor of Immunology at the Mayo Clinic and Oncolytics Scientific Advisory Board Member. “This further underscores Oncolytics’ continued commitment to define the mechanisms by which pelareorep engages the immune system and illustrates the progress being made in developing a differentiated immunotherapy to improve treatment options for difficult-to-treat cancers.”
“KRAS-mutant tumors remain among the most challenging to treat with immunotherapy,” said Jared Kelly, Chief Executive Officer of Oncolytics. “These data reflect important progress in bridging translational and clinical data and help us better understand how immune responses are activated by pelareorep. When we can point to translational and mechanistic data as the reason for clinical efficacy, it gives us confidence that our development plans are more likely to succeed.”
...
Read the full article here. -----
#4. ONCY Potential Catalyst - Announced Durability Data Points To Demonstrate Meaningful And Sustained Clinical Benefit In Patients.
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark
Company Engaged with FDA to Support Potential Accelerated Approval Pathway in 2L RAS-Mutant MSS mCRC
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate immune-sensing pathways, today announced new durability data in metastatic colorectal cancer (“mCRC”), demonstrating meaningful and sustained clinical benefit in patients with RAS-mutant, microsatellite-stable (“MSS”) disease.
...
“We believe these data demonstrate a compelling durability signal for pelareorep in colorectal cancer,” said Jared Kelly, Chief Executive Officer of Oncolytics. “A 19.5-month median duration of response in second-line patients—representing a three- to four-fold improvement over historical expectations—highlights pelareorep’s potential to deliver sustained benefit in a population with few effective options. We believe these results support a path toward accelerated approval in second-line RAS-mutant MSS metastatic colorectal cancer, and we are actively engaging with the FDA to align on a regulatory strategy leveraging our ongoing randomized study.”
...
Read the full article here. -----
#5. ONCY Potential Catalyst - A Zacks Small-Cap Research Analyst Chimes In With A $6 Target For ONCY.
Another analyst, David Bautz of Zacks Small-Cap Research, has shared a $6.00 target as of mid-May.
From its 4:00PM EST close on Friday, that targets suggests 450+% potential upside for ONCY.
Report highlights:
We look forward to additional details on the upcoming pivotal trial for pelareorep in anal cancer, for which we continue to anticipate it initiating in the second half of 2026. The updated response data for pelareorep in mCRC is very encouraging, and we look forward to updates from the company regarding the potential for accelerated approval in that indication. With no changes to our model, our valuation remains at $6 per share. -----
(Nasdaq: ONCY) Recap - 5 Potential Catalysts Hits Our Radar
#1. An Average Of 4 Analyst Targets Suggest Major Upside Potential (Triple-Digit).
#2. An Interesting Chart Position Could Put ONCY On High Alert This Week.
#3. The Company Presents Translational Data From Key Trials At ASCO 2026.
#4. Announced Durability Data Points To Demonstrate Meaningful And Sustained Clinical Benefit In Patients.
#5. A Zacks Small-Cap Research Analyst Chimes In With A $6 Target For ONCY. -----
We're initiating coverage on Oncolytics Biotech Inc. (Nasdaq: ONCY).
Be on the lookout for updates coming your way soon. Talk shortly.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 05/31/2026 and ending on 06/01/2026 to publicly disseminate information about (ONCY:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid forty thousand USD ("Funds"). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from Oncolytics Biotech Inc., the issuer of (ONCY:US).
Neither SWN Media LLC, TD Media LLC and their member own shares of (ONCY:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/oncy-x06le/#details |
0 التعليقات:
إرسال تعليق